{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:45:14Z","timestamp":1792611914110,"version":"4.5.0"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Since the approval of ibrutinib in 2016 in Canada for relapsed or refractory (R\/R) mantle cell lymphoma (MCL), there has been limited evidence characterizing treatment patterns, burden of illness, and survival in Canadian patients ineligible for autologous stem cell transplant (ASCT). This is the first study in Ontario reporting real\u2010world treatment patterns and clinical outcomes of elderly patients with MCL who are transplant\u2010ineligible in 1L and R\/R settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The aim of this study was to characterize the real\u2010world use and outcomes of patients with MCL who were \u2265 65 years old and transplant\u2010ineligible in first\u2010line (1L) and R\/R settings between 2013 and 2021 using administrative databases in Ontario, Canada. Incidence of MCL, treatment patterns, and overall survival (OS) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study cohort consisted of 754 patients (follow\u2010up: 36.1 months, median age: 76 [IQR: 71\u201382], 71.1% male). Most patients received bendamustine and rituximab in 1L (76.7%) and ibrutinib in second\u2010line (2L; 73.2%). Mortality rates following 1L and 2L therapy were 39.3% and 68.5%, respectively. Duration of therapy in 1L and 2L treatment was 4.70 and 2.14 months, respectively. Median OS decreased with subsequent lines of therapy (1L: 3.51 years; 2L: 0.60 years; third\u2010line: 0.43 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study characterized the treatment patterns, rwOS, and TTNT\u2010D of MCL patients in Ontario, Canada. Poor real\u2010world clinical outcomes support the need for additional 1L and R\/R therapies for MCL management for an ASCT\u2010ineligible population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>The authors have confirmed clinical trial registration is not needed for this submission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70384","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:53:06Z","timestamp":1792061586000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant\u2010Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada"],"prefix":"10.1002","volume":"7","author":[{"given":"Sydney","family":"George","sequence":"first","affiliation":[{"name":"Scientific Affairs BioPharmaceuticals, AstraZeneca  Mississauga Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jin","family":"Seung","sequence":"additional","affiliation":[{"name":"Health Outcomes and PharmacoEconomics (HOPE) Research Centre Sunnybrook Research Institute  North York Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thibault","sequence":"additional","affiliation":[{"name":"Scientific Affairs BioPharmaceuticals, AstraZeneca  Mississauga Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisia","family":"Wong","sequence":"additional","affiliation":[{"name":"Health Outcomes and PharmacoEconomics (HOPE) Research Centre Sunnybrook Research Institute  North York Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie A.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Scientific Affairs BioPharmaceuticals, AstraZeneca  Mississauga Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[{"name":"University Health Network  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"2","key":"e_1_2_13_2_1","first-page":"5","article-title":"Mantle Cell Lymphoma: Evolving Frontline Treatment Strategies","volume":"3","author":"Gong I. Y.","year":"2024","journal-title":"Canadian Hematology Today"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.240095"},{"key":"e_1_2_13_4_1","unstructured":"Lymphoma Canada \u201cUnderstanding Mantle Cell Lymphoma (MCL) \u201d published August 17 2022:1\u20138.https:\/\/www.lymphoma.ca\/wp\u2010content\/uploads\/2021\/10\/LymphomaCanada_FactSheet_MCL_Digital\u2010V2.pdf."},{"key":"e_1_2_13_5_1","unstructured":"AstraZenecaCanada \u201cHealth Canada Approves Calquence\u00ae with the Addition of Chemoimmunotherapy for Patients With Previously Untreated Mantle Cell Lymphoma (MCL) \u201dAstraZeneca Canada 2025."},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26523"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16010006"},{"key":"e_1_2_13_8_1","unstructured":"D. T.Lynch S.Koya S.Dogga andA.Kumar \u201cMantle Cell Lymphoma \u201d in StatPearls(StatPearls 2023):1\u20139."},{"key":"e_1_2_13_9_1","volume-title":"Mantle Cell Lymphoma","author":"Lynch D. T.","year":"2025"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00914-1"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30060418"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3149"},{"key":"e_1_2_13_13_1","unstructured":"(NCCN) NCCN \u201cNCCN Guidelines for Patients\u00ae: Mantle Cell Lymphoma \u201d2025 https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=patients&id=20."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167633"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA7502"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00690"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_609"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.311"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103212"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol-22-8"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200290"},{"key":"e_1_2_13_23_1","article-title":"Acalabrutinib Plus Bendamustine and Rituximab in Untreated Mantle Cell Lymphoma: Results From the Phase 3, Double\u2010Blind, Placebo\u2010Controlled ECHO Trial","author":"Wang M.","year":"2024","journal-title":"EHA Library"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007247"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34565"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2559"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162844"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_13_29_1","unstructured":"Leukemia & Lymphoma Society \u201cUpdated Data on Blood Cancers: Facts 2020\u20102021 \u201d2021.https:\/\/llscorp.dev2.lls.org\/sites\/default\/files\/202108\/PS80%20FactsBook_2020_2021_FINAL.pdf."},{"key":"e_1_2_13_30_1","unstructured":"United States Census Bureau \u201cAge Distribution for U.S. Population: 2000 2010 and 2020 Censuses \u201d2023 https:\/\/www.census.gov\/library\/visualizations\/interactive\/age\u2010distribution\u2010for\u2010united\u2010states\u2010population.html."},{"key":"e_1_2_13_31_1","unstructured":"Government of Canada \u201cPopulation Estimates on July 1 by Age and Gender1 2 3 4 5 \u201d2024 https:\/\/doi.org\/10.25318\/1710000501\u2010eng."},{"key":"e_1_2_13_32_1","unstructured":"U.S. Food & Drug Administration \u201cFDA Approves Acalabrutinib With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma \u201d2025 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010acalabrutinib\u2010bendamustine\u2010and\u2010rituximab\u2010previously\u2010untreated\u2010mantle\u2010cell\u2010lymphoma."},{"key":"e_1_2_13_33_1","unstructured":"Janssen Inc. \u201cIMBRUVICA (ibrutinib) Product Monograph \u201d2025.https:\/\/pdf.hres.ca\/dpd_pm\/00082633.PDF."},{"key":"e_1_2_13_34_1","unstructured":"Agency CsD. \u201cPC0402\u2010Venclexta Recommendation \u201d2025.https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2025\/PC0402Venclexta_Recommendation.pdf."},{"key":"e_1_2_13_35_1","unstructured":"BeiGene Ltd. \u201cHealth Canada Approves BRUKINSA\u00ae (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL) the Most Common Leukemia in Adult \u201d2023.https:\/\/www.newswire.ca\/news-releases\/health-canada-approves-pr-brukinsa-r-zanubrutinib-for-the-treatment-of-chronic-lymphocytic-leukemia-cll-the-most-common-leukemia-in-adults-816531975.html."},{"key":"e_1_2_13_36_1","unstructured":"Canada's Drug Agency\u2010L'Agence des medicaments du Canada \u201cProvincial Funding Summary \u2013 Ibrutinib (Imbruvica) for Mantle Cell Lymphoma (Relapsed\/Refractory) (pCODR 10073) \u201d2018.https:\/\/www.cda-amc.ca\/sites\/default\/files\/pcodr\/pcodrprovfund_ibrutinib_imbruvica_mcl.pdf."},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2234525"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70094_269"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.04.1588"},{"key":"e_1_2_13_40_1","first-page":"1365","article-title":"Outcomes in 370 Patients With Mantle Cell Lymphoma Treated With Ibrutinib: A Pooled Analysis From Three Open\u2010Label Studies","volume":"14","author":"Rule S. A.\u2010O.","year":"2017","journal-title":"British Journal of Haematology"},{"key":"e_1_2_13_41_1","unstructured":"Lymphoma Canada. \u201cUnderstanding Rituxan use in Canada [Internet].\u201d [cited 2026 Sep 11].https:\/\/www.lymphoma.ca\/understanding-rituxan-use-in-canada\/."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70384","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:19:16Z","timestamp":1792610356000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/jha2.70384"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70384","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70384"}}